The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rechallenge with oxaliplatin and fluoropyrimidine (FOX) after prior therapy in metastatic colorectal carcinoma (mCRC).
A. R. Townsend
No relevant relationships to disclose
V. Broadbridge
No relevant relationships to disclose
C. Beeke
No relevant relationships to disclose
C. S. Karapetis
No relevant relationships to disclose
S. Bishnoi
No relevant relationships to disclose
K. Jain
No relevant relationships to disclose
C. Luke
No relevant relationships to disclose
R. Padbury
No relevant relationships to disclose
T. J. Price
No relevant relationships to disclose